Drugmaker AbbVie has agreed to license a weight-loss drug currently in development from Gubra for up to about $2.2 billion, marking its entry into the obesity treatment market.
Over 30 state attorneys general including in Indiana, Kentucky, and Ohio have urged the Federal Food and Drug Administration ...
Consumers who use telehealth or medical spas to get less expensive, compounded weight loss drugs will need to get their ...
Nearly one-third of adult employees would change jobs in order to gain coverage. As the demand for GLP-1 weight loss ...
What the telehealth prescribers can’t do, the compounders are. A major drug compounder association, the Outsourcing Facilities Association, along with member North American Custom Laboratories, LLC, ...
Last week, the US Food and Drug Administration (FDA) announced the end of a years-long shortage of semaglutide injection products — a ...
New diabetes medications are pressuring Medicare Part D financially as they drive up prescription drug costs amid rising ...
Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...
Despite the continued success of GLP-1 drugs Ozempic and Wegovy, Novo Nordisk CEO Lars Fruergaard Jørgensen took a slight pay cut in 2024. He received 57.1 million Danish kroner (DKK) – $8 million – ...
Today we'll look at six European stocks that could continue outperforming in 2025. Some of these companies are available to ...
A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms ...
Medicare spending on some diabetes drugs, including popular treatments such as Ozempic, surged nearly five-fold to $35.8 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback